Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes Japanese encephalitis (JE), a severe neurological disease. The primary vector for JEV transmission is the Culex mosquito, particularly Culex tritaeniorhynchus. The virus primarily circulates in an enzootic cycle involving pigs and wading birds, with humans serving as incidental hosts. The virus is prevalent in certain regions of Asia, including parts of Southeast Asia, the Indian subcontinent, and the Far East. JEV transmission occurs in rural and peri-urban areas, where rice fields and pig farming provide suitable breeding grounds for mosquitoes. The virus is maintained in a complex cycle involving amplification in pigs and transmission to humans through mosquito bites. In endemic areas, JE outbreaks often coincide with the monsoon season when mosquito populations peak. Clinical manifestations of Japanese encephalitis range from mild febrile illness to severe encephalitis with neurological complications. The disease has a significant impact on pediatric populations, and survivors may experience long-term neurological sequelae. Preventive measures for Japanese encephalitis include vaccination, vector control, and health education. Vaccination campaigns target high-risk populations, such as children in endemic areas, and have contributed to a reduction in JE cases in some regions.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain